^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Ampulla of Vater Carcinoma |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
Excerpt:
Two patients harbouring activating hotspot mutations in PIK3CA were identified. One of these patients who had a previously resected T2N0 ampullary carcinoma with intestinal differentiation and received adjuvant gemcitabine 2 years before enrolment in this study had a prolonged PFS on everolimus (16.7 months).
DOI:
10.1038/s41416-018-0021-1
Trial ID:
